GlassScriptPhysician profile
Richard Hope
NPI 1457346819
$9,720.23
in general payments reported to CMS, 2019-2025
35 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $1,144 · 2021: $1,114 · 2022: $1,168 · 2023: $1,973 · 2024: $1,386 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,419 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,418.59 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.61 | 2019-2025 | |
| Amgen INC. | $918.99 | 2020-2025 | Otezla, Otezla, Enbrel |
| Allergan, INC. | $805.91 | 2019-2022 | |
| Janssen Biotech, INC. | $699.79 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $652.77 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $561.83 | 2019-2025 | Sotyktu |
| Leo Pharma INC. | $429.54 | 2022-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $424.51 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $381.44 | 2019-2025 | |
| Galderma Laboratories, L.P. | $344.19 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $309.63 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genentech USA, INC. | $191.98 | 2019-2024 | Xolair |
| Ucb, INC. | $183.72 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $174.46 | 2019-2024 | |
| Celgene Corporation | $161.24 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $123.28 | 2022-2023 | |
| Revance Therapeutics, INC. | $121.41 | 2024-2025 | Daxxify |
| Pfizer INC. | $110.46 | 2019-2023 | |
| Krystal Biotech INC | $105.78 | 2024-2025 | Vyjuvek |
| Biofrontera INC. | $102.38 | 2019-2020 | |
| Incyte Corporation | $81.67 | 2023-2025 | Opzelura |
| Organon LLC | $48.16 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.71 | 2021 | |
| Mayne Pharma Commercial LLC | $36.64 | 2020-2023 | |
| Springworks Therapeutics, INC. | $28.99 | 2025 | Gomekli |
| Dusa Pharmaceuticals, INC. | $20.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $18.51 | 2024 | Nuzyra |
| Organogenesis INC. | $17.35 | 2025 | Affinity |
| Urgo Medical North America, LLC | $17.08 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Merz North America, INC. | $14.10 | 2023 | Xeomin |
| Arcutis Biotherapeutics, INC. | $13.67 | 2023 | |
| Nabriva Therapeutics, Plc | $13.62 | 2020 | |
| Smith+Nephew, INC. | $12.81 | 2023 | Regranex, Collagenase Santyl, Iodosorb Ointment 40g USA |
| Kerecis Limited | $10.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.